uniQure N.V. $QURE Stock Holdings Lessened by Monaco Asset Management SAM

Monaco Asset Management SAM cut its stake in shares of uniQure N.V. (NASDAQ:QURE) by 6.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,000 shares of the biotechnology company’s stock after selling 5,000 shares during the period. Monaco Asset Management SAM’s holdings in uniQure were worth $976,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vestal Point Capital LP boosted its stake in shares of uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after buying an additional 1,767,572 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after acquiring an additional 101,598 shares in the last quarter. Aberdeen Group plc boosted its position in uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after purchasing an additional 535,163 shares during the last quarter. 683 Capital Management LLC boosted its position in uniQure by 1.6% during the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company’s stock valued at $16,430,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its stake in uniQure by 27.5% in the first quarter. Lord Abbett & CO. LLC now owns 400,785 shares of the biotechnology company’s stock valued at $4,248,000 after purchasing an additional 86,372 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on QURE shares. HC Wainwright cut their price target on uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday. Royal Bank Of Canada cut their price objective on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research report on Monday, November 3rd. Mizuho lifted their target price on shares of uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. William Blair lowered shares of uniQure from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, Leerink Partners raised their price target on shares of uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a report on Wednesday, September 24th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average price target of $66.75.

uniQure Trading Up 1.0%

NASDAQ:QURE opened at $27.79 on Friday. uniQure N.V. has a 12 month low of $5.50 and a 12 month high of $71.50. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -7.09 and a beta of 0.59. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The company’s 50 day moving average is $42.07 and its 200-day moving average is $24.23.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer owned 651,454 shares in the company, valued at $27,009,282.84. This trade represents a 25.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer owned 217,730 shares of the company’s stock, valued at $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 283,126 shares of company stock worth $11,505,677. 4.79% of the stock is owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.